Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
NEW YORK, December 31, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Aetna Inc. (NYSE: AET), United Therapeutics Corporation (NASDAQ: UTHR), Perrigo Co. (NYSE: PRGO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Aetna Inc. Research Report
On December 19, 2013, Aetna Inc. (Aetna), along with Arizona Care Network, announced an accountable care collaboration and the introduction of Arizona Care Network Plans, an Aetna Whole HealthSM product. The Company informed that Aetna Whole Health is a collection of benefits plans to offer members access to highly coordinated care from the physicians and facilities in the Arizona Care Network. Aetna added that the health plans are designed for fully insured and self-insured employers in Maricopa County and can be availed beginning January 1, 2014. Tom Dameron, Company President for Arizona Operations, stated, "Working together, Aetna and Arizona Care Network will deliver high quality, comprehensive health care to our customers and their employees in Maricopa County. This agreement with Arizona Care Network is just the latest example of Aetna's commitment to working with medical providers across the country to provide better value and improved outcomes for our members." The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to dPage: 1 2 3 4 5 Related biology technology :1
. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline2
. California Biomedical Companies Report Higher Product Approvals, Fewer Delays3
. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge4
. Synthetic Biologics Announces Proposed Public Offering of Common Stock5
. MiMedx Group Announces Proposed Public Offering of Common Stock6
. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC7
. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants8
. Z Trim Holdings, Inc. Announces Pricing of Public Offering of Common Stock and Warrants9
. DURECT Announces Pricing of Public Offering of Common Stock10
. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock11
. Discovery Labs Prices $50 Million Public Offering of Common Stock
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers. B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ... Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....Biology Products: